Literature DB >> 7988721

Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin.

H Lu1, P Yeh, J D Guitton, C Mabilat, F Desanlis, I Maury, Y Legrand, J Soria, C Soria.   

Abstract

Receptor-bound urokinase is likely to be a crucial determinant in both tumor invasion and angiogenesis. We report here that a yeast-derived genetic conjugate between human serum albumin and the 1-135 N-terminal residues of urokinase (u-PA) competitively inhibits the binding of exogenous and endogenous u-PA to its cell-anchored receptor (u-PAR). This hybrid molecule (ATF-HSA) also inhibits in vitro pro-urokinase-dependent plasminogen activation in the presence of u-PAR bearing cells. These effects are probably responsible for the observed in vitro inhibition of tumor cell invasion in a reconstituted basement membrane extract (Matrigel).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988721     DOI: 10.1016/0014-5793(94)01237-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  The inhibitory effects of an antisense u-PAR vector on invasion of highly invasive human prostate carcinoma PC-3M cell subclones.

Authors:  Guoning Liao; Qingfen Li; Youmei Feng; Yaozu Deng; Zhuoya Li; Feili Gong; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

2.  Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.

Authors:  D M Ignar; J L Andrews; S M Witherspoon; J D Leray; W C Clay; K Kilpatrick; J Onori; T Kost; D L Emerson
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

Review 3.  Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy.

Authors:  Dan Li; Shuanglong Liu; Hong Shan; Peter Conti; Zibo Li
Journal:  Theranostics       Date:  2013-06-29       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.